Petition Denied: The United States Supreme Court Refuses to Reconsider Patent Eligibility Jurisprudence
On January 13, 2020, the Supreme Court of the United States denied certiorari in three pending cases:
Athena Diagnostics, Inc. v. Mayo Collaborative
(19-430), HP Inc. v. Berkheimer (18-415), Hikma Pharmaceuticals USA Inc. v. Vanda Pharmaceuticals Inc. (18-817). These three cases were likely the best opportunity for the Supreme Court to reconsider their holding in Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014) for many years. Following these denials, the Supreme Court is unlikely to address substantive standards for patent-eligibility in the immediate future, and thus Congress is now left with the task of fixing the resulting confusion prevalent among the lower courts.